VAXIL revises private placement terms to raise up to $350,000

Vaxil Bio Ltd. (TSX VENTURE: VXL) announced revisions to its previously disclosed private placement offering, now targeting up to $350,000 in gross proceeds through the sale of 3,111,111 units priced at $0.1125 each.

Each unit consists of one common share and one share purchase warrant. The warrants allow holders to purchase additional shares at $0.15 per share for five years following the offering's completion.

The company expects to close the offering around December 4, 2025, subject to TSX Venture Exchange approval and other conditions. Net proceeds will support general corporate purposes.

Vaxil has agreed to pay finders a cash commission of up to 8% of gross proceeds and issue non-transferrable warrants representing up to 8% of the total units sold. All securities will be subject to a four-month-and-one-day hold period from the issue date.

The Israeli company previously focused on immunotherapy treatments for cancer and infectious diseases, with its lead product ImMucin receiving orphan drug status from the FDA and European Medicines Agency. Vaxil stated it is currently evaluating other business opportunities that may or may not be in biotechnology to enhance shareholder value.

The announcement follows the company's October 29, 2025 news release regarding the original offering terms, according to the press release statement.

You May Also Be Interested In

• GoldInxs Mining launches $1.15M private placement offering
• Lucid Capital Markets Starts LENSAR Inc. (LNSR) at Buy
• FTAI Infrastructure unit to buy crude oil assets from USD Group for $255M